Covista Inc. CVSA · NYSE
$128.55 +1.42% (+$1.80)
Summary
86 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 13 USD is left as net profit.
- Revenue grew by 11% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- It bought back its own shares for $239.9M in the last fiscal year, 5.5% of its market value.
What to watch
- Earnings per share fell by 23% a year over the last 3 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 17.3 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 11% a year. Earnings per share fell by 23% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 43 USD
- Sales and administration 38 USD
- Taxes and other 6.8 USD
- Net profit 13 USD
Net profit, industry median (Education & Training Services) 8.4 USD
Out of every 100 USD of revenue, 13 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.3 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $153.33 is 19% above today's price. 67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.